157 related articles for article (PubMed ID: 18272304)
1. Application and limitation of inhibitors in drug-transporter interactions studies.
Wang Q; Strab R; Kardos P; Ferguson C; Li J; Owen A; Hidalgo IJ
Int J Pharm; 2008 May; 356(1-2):12-8. PubMed ID: 18272304
[TBL] [Abstract][Full Text] [Related]
2. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
3. Formation and efflux of ATP-binding cassette transporter substrate 2,4-dinitrophenyl-S-glutathione from cultured human term placental villous tissue fragments.
Vaidya SS; Walsh SW; Gerk PM
Mol Pharm; 2009; 6(6):1689-702. PubMed ID: 19397308
[TBL] [Abstract][Full Text] [Related]
4. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
[TBL] [Abstract][Full Text] [Related]
5. Interactions of cyclosporin a with breast cancer resistance protein.
Xia CQ; Liu N; Miwa GT; Gan LS
Drug Metab Dispos; 2007 Apr; 35(4):576-82. PubMed ID: 17220244
[TBL] [Abstract][Full Text] [Related]
6. Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.
Kwatra D; Vadlapatla RK; Vadlapudi AD; Pal D; Mitra AK
Int J Pharm; 2010 Aug; 395(1-2):114-21. PubMed ID: 20573570
[TBL] [Abstract][Full Text] [Related]
7. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
[TBL] [Abstract][Full Text] [Related]
8. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
9. Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells.
Kamiyama E; Sugiyama D; Nakai D; Miura S; Okazaki O
Drug Metab Dispos; 2009 Sep; 37(9):1956-62. PubMed ID: 19505989
[TBL] [Abstract][Full Text] [Related]
10. Presence or absence of a gallate moiety on catechins affects their cellular transport.
Kadowaki M; Sugihara N; Tagashira T; Terao K; Furuno K
J Pharm Pharmacol; 2008 Sep; 60(9):1189-95. PubMed ID: 18718123
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.
Miller DW; Hinton M; Chen F
Neurourol Urodyn; 2011 Nov; 30(8):1633-8. PubMed ID: 21826715
[TBL] [Abstract][Full Text] [Related]
12. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine.
Dahan A; Sabit H; Amidon GL
Drug Metab Dispos; 2009 Oct; 37(10):2028-36. PubMed ID: 19589874
[TBL] [Abstract][Full Text] [Related]
13. Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.
Salphati L; Plise EG; Li G
Eur J Pharm Sci; 2009 Jun; 37(3-4):463-8. PubMed ID: 19491037
[TBL] [Abstract][Full Text] [Related]
14. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Lin X; Skolnik S; Chen X; Wang J
Drug Metab Dispos; 2011 Feb; 39(2):265-74. PubMed ID: 21051535
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response.
Alvarez AI; Real R; Pérez M; Mendoza G; Prieto JG; Merino G
J Pharm Sci; 2010 Feb; 99(2):598-617. PubMed ID: 19544374
[TBL] [Abstract][Full Text] [Related]
17. Silencing the breast cancer resistance protein expression and function in caco-2 cells using lentiviral vector-based short hairpin RNA.
Zhang W; Li J; Allen SM; Weiskircher EA; Huang Y; George RA; Fong RG; Owen A; Hidalgo IJ
Drug Metab Dispos; 2009 Apr; 37(4):737-44. PubMed ID: 19131524
[TBL] [Abstract][Full Text] [Related]
18. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
19. Disposition mechanisms of raloxifene in the human intestinal Caco-2 model.
Jeong EJ; Lin H; Hu M
J Pharmacol Exp Ther; 2004 Jul; 310(1):376-85. PubMed ID: 15020665
[TBL] [Abstract][Full Text] [Related]
20. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake.
Gutmann H; Fricker G; Török M; Michael S; Beglinger C; Drewe J
Pharm Res; 1999 Mar; 16(3):402-7. PubMed ID: 10213371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]